Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 3/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18253254 | 1.00 | GABRR1 (0.43) | GABRR1SLC1A2CYP2C9CYP2C19GRM8 | |
| SCHEMBL16380722 | 1.00 | GABRR1 (0.43) | GABRR1SLC1A2CYP2C9CYP2C19GRM8 | |
| SCHEMBL17484815 | 1.00 | GABRR1 (0.43) | GABRR1SLC1A2CYP2C9CYP2C19GRM8 | |
| SCHEMBL30756696 | 1.00 | GABRR1 (0.43) | GABRR1SLC1A2CYP2C9CYP2C19GRM8 | |
| SCHEMBL28265022 | 0.88 | — | — | |
| SCHEMBL14191347 | 0.81 | GABRR1 (0.42) | GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL22602662 | 0.81 | GABRR1 (0.42) | GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL19762835 | 0.81 | GABRR1 (0.42) | GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL4083282 | 0.79 | GABRR1 (0.50) | GABRR1SLC1A2CYP2C9CYP2C19GRM8 | |
| SCHEMBL3742301 | 0.79 | GABRR1 (0.50) | GABRR1SLC1A2CYP2C9CYP2C19GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342777-B2 | Caffeoylquinic acid-rich extract and preparation as well as use thereof | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2019-07-09 | — | — | US | disclosed |
| US-20180002275-A1 | HYPDH INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF KIDNEY STONES | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2018-01-04 | — | — | US | disclosed |
| US-20170095443-A1 | CAFFEOYLQUINIC ACID-RICH EXTRACT AND PREPARATION AS WELL AS USE THEREOF | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-04-06 | — | — | US | disclosed |
| US-20150038668-A1 | Branched Polyesters Based On Citric Acid, Their Preparation And Use | BASF SE (DE) | 2015-02-05 | — | — | US | disclosed |
| EP-2611852-B1 | BRANCHED POLYESTERS BASED ON CITRIC ACID AND ALSO THEIR PREPARATION AND USE | BASF SE (DE) | 2014-07-30 | — | — | EP | disclosed |
| EP-2611852-A1 | BRANCHED POLYESTERS BASED ON CITRIC ACID AND ALSO THEIR PREPARATION AND USE | BASF SE (DE) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028496-A1 | BRANCHED POLYESTERS BASED ON CITRIC ACID AND ALSO THEIR PREPARATION AND USE | BASF SE (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2118079-A1 | SYNTHETIC MACROCYCLIC COMPOUNDS FOR TREATING CANCER | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008098138-A1 | SYNTHETIC MACROCYCLIC COMPOUNDS FOR TREATING CANCER | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-08-14 | — | — | WO | disclosed |
| CN-101142211-A | Process and method for preparing optically active cis-2-hydroxymethyl-4- (cytosin-1' -yl) -1, 3-oxathiolane or pharmaceutically acceptable salts thereof | SERRE BIOLOG CHEMISTRY COMPANY (CA) | 2008-03-12 | — | — | CN | disclosed |
| EP-1009398-A4 | MOLECULAR COMPLEX AND CONTROL-RELEASE OF ALPHA HYDROXYACIDS | YU RUEY J (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1009398-A1 | MOLECULAR COMPLEX AND CONTROL-RELEASE OF ALPHA HYDROXYACIDS | Yu, Ruey J., Dr. (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1998046217-A1 | MOLECULAR COMPLEX AND CONTROL-RELEASE OF ALPHA HYDROXYACIDS | YU RUEY J (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095443-A1 | CAFFEOYLQUINIC ACID-RICH EXTRACT AND PREPARATION AS WELL AS USE THEREOF | CHCHD6, FABP3, TNNT2 | GABRR1 540/4885SLC1A2 1196/4885CYP2C9 1687/4885 |
| US-20180002275-A1 | HYPDH INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF KIDNEY STONES | XDH, GLS, GRHPR | GABRR1 1840/4885SLC1A2 1748/4885CYP2C9 633/4885 |
| US-10342777-B2 | Caffeoylquinic acid-rich extract and preparation as well as use thereof | CHCHD6, FABP3, TNNT2 | GABRR1 540/4885SLC1A2 1196/4885CYP2C9 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.